Amino-Terminal Pro-B-Type Natriuretic Peptide Testing in Patients with Diabetes Mellitus and with Systemic Hypertension

American Journal of Cardiology

Volumn 101, Issue 3 SUPPL., 2008, Pages

  Hildebrandt, Per ^a   Richards, A Mark ^b  

^a ROSKILDE HOSPITAL   (Denmark)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; DIABETES MELLITUS; HEART DISEASE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PRIORITY JOURNAL; PROGNOSIS; SCREENING; TREATMENT INDICATION;

BIOLOGICAL MARKERS; DIABETES MELLITUS; HUMANS; HYPERTENSION; MASS SCREENING; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN PRECURSORS; RISK FACTORS;

EID: 38649137693     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.11.015     Document Type: Article

References (19)

1. Hildebrandt P., and Collinson P. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol 101 (2008) 25A-28A
2. Costello-Boerrigter L.C., Boerrigter G., Redfield M.M., Rodeheffer R.J., Urban L.H., Mahoney D.W., Jacobsen S.J., Heublein D.M., and Burnett Jr. J.C. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47 (2006) 345-353
3. Heidenreich P.A., Gubens M.A., Fonarow G.C., Konstam M.A., Stevenson L.W., and Shekelle P.G. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43 (2004) 1019-1026
4. Nielsen O.W., McDonagh T.A., Robb S.D., and Dargie H.J. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 41 (2003) 113-120
5. Galasko G.I., Barnes S.C., Collinson P., Lahiri A., and Senior R. What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?. Eur Heart J 27 (2006) 193-200
6. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., and Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004) 1879-1884
7. Amato L., Paolisso G., Cacciatore F., Ferrara N., Ferrara P., Canonico S., Varricchio M., Rengo F., and Osservatorio Geriatrico Regione Campania Group. Congestive heart failure predicts the development of non-insulin-dependent diabetes mellitus in the elderly. Diabetes Metab 23 (1997) 213-218
8. Kistorp C., Raymond I., Pedersen F., Gustafsson F., Faber J., and Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA 293 (2005) 1609-1616
9. Epshteyn V., Morrison K., Krishnaswamy P., Kazanegra R., Clopton P., Mudaliar S., Edelman S., Henry R., and Maisel A. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 26 (2003) 2081-2087
10. Bhalla M.A., Chiang A., Epshteyn V.A., Kazanegra R., Bhalla V., Clopton P., Krishnaswamy P., Morrison L.K., Chiu A., Gardetto N., et al. Prognostic role of B-type natriuretic peptide levels in patients with type 2 diabetes mellitus. J Am Coll Cardiol 44 (2004) 1047-1052
11. Tarnow L., Hildebrandt P., Hansen B.V., Borch-Johnsen K., and Parving H.H. Plasma N-terminal pro-brain natriuretic peptide as an independent predictor of mortality in diabetic nephropathy. Diabetologia 48 (2005) 149-155
12. Gaede P., Hildebrandt P., Hess G., Parving H.H., and Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 48 (2005) 156-163
13. Olsen M.H., Hansen T.W., Christensen M.K., Gustafsson F., Rasmussen S., Wachtell K., Borch-Johnsen K., Ibsen H., Jorgensen T., and Hildebrandt P. N-terminal pro brain natriuretic peptide is inversely related to metabolic cardiovascular risk factors and the metabolic syndrome. Hypertension 46 (2005) 660-666
14. Hildebrandt P., Boesen M., Olsen M., Wachtell K., and Groenning B. N-terminal pro brain natriuretic peptide in arterial hypertension-a marker for left ventricular dimensions and prognosis. Eur J Heart Fail 6 (2004) 313-317
15. Vasan R.S., Benjamin E.J., Larson M.G., Leip E.P., Wang T.J., Wilson P.W., and Levy D. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. JAMA 288 (2002) 1252-1259
16. Olsen M.H., Wachtell K., Nielsen O.W., Hall C., Wergeland R., Ibsen H., Kjeldsen S.E., Devereux R.B., Dahlof B., and Hildebrandt P.R. N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy. J Hypertens 24 (2006) 1531-1539
17. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325 (1991) 293-302
18. Blankenberg S., McQueen M.J., Smieja M., Pogue J., Balion C., Lonn E., Rupprecht H.J., Bickel C., Tiret L., Cambien F., et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 114 (2006) 201-208
19. Emberson J.R., Ng L.L., Armitage J., Bowman L., Parish S., and Collins R. N-terminal Pro-B-type natriuretic peptide, vascular disease risk, and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 49 (2007) 311-319